SINTX Technologies (SINT) Q3 2025 earnings summary

Executive summary

• Achieved FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, enabling entry into the U.S. reconstructive foot and ankle surgery market, with commercial revenue expected in 2026.

• Recorded first commercial revenue from OsseoSculpt™, a companion biologic product.

• Focus shifted to proprietary silicon nitride-based biomedical devices, reducing non-core OEM contracts to improve long-term profitability and margins.

• Sold TA & T subsidiary and ceased efforts to operationalize the armor plant, streamlining operations and reducing costs.

• Broadened intellectual property portfolio with a new patent allowance for antipathogenic fabric technology.

Financial highlights

• Total revenue for the nine months ended September 30, 2025, was $0.7M, down 67% year-over-year due to strategic repositioning.

• Q3 2025 revenue was $0.2M, down from $0.8M in Q3 2024, mainly due to lower grant revenue.

• Net loss for the nine months was $8.1M, an improvement from $9.3M in the prior year period.

• Operating expenses decreased 51% year-over-year to $3.4M in Q3 2025.

• Cash and cash equivalents increased to $6.3M as of September 30, 2025, from $3.6M at year-end 2024.

Outlook and guidance

• Revenue from the new foot and ankle system is expected to begin in the first half of 2026.

• Near-term priorities include launching the SiNAPTIC wedge system, expanding clinical and KOL engagement, and leveraging material science for new indications such as 3D printed implants.

• Management believes existing capital resources are sufficient to continue as a going concern through at least November 2026.

• Strategic focus remains on high-growth healthcare applications leveraging silicon nitride technology.

• Management will continue to evaluate partnerships, licensing, and capital formation to accelerate market access and enhance shareholder value.